



Improvement of daytime hypercapnia with nocturnal non-invasive ventilation in familial dysautonomia

Horacio Kaufmann¹ · Lucy Norcliffe-Kaufmann¹ · Jose-Alberto Palma¹ 

Received: 20 December 2018 / Accepted: 7 January 2019 / Published online: 12 January 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Dear Editors,

Chemoreceptor failure is a dramatic feature of familial dysautonomia (FD), a rare genetic disease caused by a founder mutation in the IκB kinase-associated protein gene (*IKBKAP*) [1–3]. As a consequence, ventilatory responses to hypercapnia are reduced, and those to hypoxia are almost absent. In response to hypoxia, patients can develop paradoxical hypoventilation, hypotension, bradycardia, and potentially death [4–7]. Chemoreflex failure can be devastating during sleep when conscious control of respiration withdraws. Virtually all patients with FD have some degree of sleep-disordered breathing [3, 7], which is a risk factor for sudden unexpected death during sleep [2].

Nocturnal non-invasive ventilation with bi-level positive pressure (BiPAP) reduces daytime hypercapnia in patients with neuromuscular disease, such as Duchenne muscular dystrophy [8, 9], suggesting that nocturnal non-invasive ventilation improves daytime respiratory drive by resetting peripheral and/or central chemoreceptor function [10]. We hypothesized that a similar chemoreceptor reflex resetting occurred in patients with FD after nocturnal non-invasive ventilation. To test this hypothesis, we obtained daytime arterial blood gases in 18 consecutive patients [10 women, 8 men, aged 28 ± 11.7 (mean \pm standard deviation) years old] with genetically confirmed FD that were not being treated with non-invasive ventilation, despite having some degree of sleep-disordered breathing. Daytime arterial blood

gases were measured at baseline before patients began treatment with nocturnal non-invasive ventilation [BiPAP in all cases except one using continuous positive airway pressure (CPAP)] and arterial blood gases were again obtained at variable follow-up times (ranging from 6 weeks to 6 months) after initiation of nocturnal non-invasive ventilation. Daytime blood gases after receiving non-invasive ventilation showed that their $p\text{CO}_2$ decreased from 45.9 ± 5.1 to 41.4 ± 4.7 mmHg (paired *T* test, $P < 0.0001$); and their $p\text{O}_2$ remained stable (from 84.2 ± 14.7 to 91 ± 16 mmHg; paired *T* test, $P = 0.1167$), as did their pH (7.4 ± 0.04 before and after non-invasive ventilation) (Fig. 1).

As nocturnal non-invasive ventilation virtually eliminated diurnal CO_2 retention in patients with FD, it is possible that the procedure, by normalizing $p\text{CO}_2$ during the night, resets the chemoreflexes to operate at lower CO_2 values, a mechanism postulated in patients with neuromuscular disorders. If confirmed in larger studies, our findings may have clinical implications, as diurnal hypercapnia has been associated with poor prognosis in patients with sleep-disordered breathing [11].

✉ Horacio Kaufmann
Horacio.Kaufmann@nyumc.org

¹ Department of Neurology, Dysautonomia Center, New York University School of Medicine, 530 First Avenue, Suite 9Q, New York, NY 10016, USA




Fig. 1 Arterial blood gas concentrations during wakefulness (daytime) before (Pre-NIV) and after non-invasive ventilation (Post-NIV). Treatment with non-invasive ventilation in patients with familial dysautonomia resulted in significantly reduced arterial pCO₂ concentration during daytime ($P < 0.0001$, left panel), suggesting that nocturnal non-invasive ventilation could reset the chemoreceptor during daytime. Nocturnal non-invasive ventilation did not change arterial pO₂ levels ($P = 0.1167$, right panel)

Funding National Institutes of Health (U54-NS065736-01) and Familial Dysautonomia Foundation, Inc.

Compliance with ethical standards

Conflict of interest Dr. Kaufmann receives funding support from the Familial Dysautonomia Foundation and is Editor in Chief of *Clinical Autonomic Research*. Dr. Palma receives funding support from the Familial Dysautonomia Foundation and is Managing Editor of *Clinical Autonomic Research*. Dr. Norcliffe-Kaufmann receives funding support from the Familial Dysautonomia Foundation.

References

1. Norcliffe-Kaufmann L, Slaugenhaupt SA, Kaufmann H (2017) Familial dysautonomia: history, genotype, phenotype and translational research. *Prog Neurobiol* 152:131–148
2. Palma JA, Norcliffe-Kaufmann L, Perez MA, Spalink CL, Kaufmann H (2017) Sudden unexpected death during sleep in familial dysautonomia: a case-control study. *Sleep* 40:zsx083. <https://doi.org/10.1093/sleep/zsx083>
3. Singh K, Palma JA, Kaufmann H, Tkachenko N, Norcliffe-Kaufmann L, Spalink C, Kazachkov M, Kothare SV (2018) Prevalence and characteristics of sleep-disordered breathing in familial dysautonomia. *Sleep Med* 45:33–38
4. Bernardi L, Hilz M, Stemper B, Passino C, Welsch G, Axelrod FB (2003) Respiratory and cerebrovascular responses to hypoxia and hypercapnia in familial dysautonomia. *Am J Respir Crit Care Med* 167:141–149
5. Edelman NH, Cherniack NS, Lahiri S, Richards E, Fishman AP (1970) The effects of abnormal sympathetic nervous function upon the ventilatory response to hypoxia. *J Clin Invest* 49:1153–1165
6. Filler J, Smith AA, Stone S, Dancis J (1965) Respiratory control in familial dysautonomia. *J Pediatr* 66:509–516
7. McNicholas WT, Rutherford R, Grossman R, Moldofsky H, Zamel N, Phillipson EA (1983) Abnormal respiratory pattern generation during sleep in patients with autonomic dysfunction. *Am Rev Respir Dis* 128:429–433
8. Hukins CA, Hillman DR (2000) Daytime predictors of sleep hypoventilation in Duchenne muscular dystrophy. *Am J Respir Crit Care Med* 161:166–170
9. Ward S, Chatwin M, Heather S, Simonds AK (2005) Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia. *Thorax* 60:1019–1024
10. Dempsey JA, Smith CA (2014) Pathophysiology of human ventilatory control. *Eur Respir J* 44:495–512
11. Kawata N, Terada J, Tatsumi K (2016) Persistent daytime hypercapnia predicts poor prognosis in OSAS undergoing CPAP therapy. *Eur Respir J* 48:PA3424